The prognostic value of exercise-induced pulmonary hypertension in asymptomatic patients with primary mitral regurgitation

Background: We examined whether the early development of exercise-induced pulmonary hypertension (EIPH) and right ventricular dysfunction during exercise stress echocardiography (ESE) may predict clinical deterioration in so-called "asymptomatic" patients with primary, at least moderate mitral regurgitation (MR). Methods: 79 consecutive patients underwent a symptom-limited, graded ESE protocol on semi-supine bicycle at the beginning of the study. During the test, we assessed symptom development, test duration, and the following echocardiographic parameters: MR severity, maximum velocity of the tricuspid regurgitation jet (TR Vmax), pulmonary artery systolic pressure (PASP), and tricuspid annulus systolic excursion (TAPSE). All patients were then followed-up for at least 12 months for clinical end-points (heart failure-related symptoms requiring pharmaceutical therapy, heart failure hospitalization, and/or mitral valve surgery in case of refractory symptoms). Results: After 16 +/- 4 months of follow-up, 75 patients completed the study; 26 of them achieved any clinical end-point and were classified as 'high-risk', while the rest (49 patients) were assigned to the 'low-risk' group. High-risk group showed significantly higher exercise-induced TR Vmax and PASP levels at maximum workload of ESE than low-risk counterparts (p < 0.001). Based on receiver operating characteristic analysis, the early (within the first two stages of ESE or up to 50 W) steep rise of calculated PASP >51 mmHg (TR Vmax >3.4 m/s) had a 92.3% sensitivity and 100% specificity to predict clinical deterioration within the following year. That cut-off value seemed superior predictor than peak value of PASP at the end of ESE. TAPSE levels during ESE did not add prognostic value in our sample. Conclusion: This is the first study demonstrating that the early development of EIPH has prognostic value in asymptomatic patients with primary at least moderate MR and may become a new valid determinant of mitral valve surgery. Additional larger prospective studies are needed to validate our findings. (c) 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.